[HTML][HTML] Cancer hallmarks, biomarkers and breast cancer molecular subtypes

X Dai, L Xiang, T Li, Z Bai - Journal of cancer, 2016 - ncbi.nlm.nih.gov
Breast cancer is a complex disease encompassing multiple tumor entities, each
characterized by distinct morphology, behavior and clinical implications. Besides estrogen …

[HTML][HTML] Breast cancer in low-middle income countries: abnormality in splicing and lack of targeted treatment options

FZ Francies, R Hull, R Khanyile… - American journal of …, 2020 - ncbi.nlm.nih.gov
Breast cancer is a common malignancy among women worldwide. Regardless of the
economic status of a country, breast cancer poses a burden in prevention, diagnosis and …

Oncogenic lncRNA downregulates cancer cell antigen presentation and intrinsic tumor suppression

Q Hu, Y Ye, LC Chan, Y Li, K Liang, A Lin… - Nature …, 2019 - nature.com
How tumor cells genetically lose antigenicity and evade immune checkpoints remains
largely elusive. We report that tissue-specific expression of the human long noncoding RNA …

Kinome screen of ferroptosis reveals a novel role of ATM in regulating iron metabolism

PH Chen, J Wu, CKC Ding, CC Lin, S Pan… - Cell Death & …, 2020 - nature.com
Ferroptosis is a specialized iron-dependent cell death that is associated with lethal lipid
peroxidation. Modulation of ferroptosis may have therapeutic potential since it has been …

Moringa oleifera as an Anti-Cancer Agent against Breast and Colorectal Cancer Cell Lines

AK Al-Asmari, SM Albalawi, MT Athar, AQ Khan… - PloS one, 2015 - journals.plos.org
In this study we investigated the anti-cancer effect of Moringa oleifera leaves, bark and seed
extracts. When tested against MDA-MB-231 and HCT-8 cancer cell lines, the extracts of …

Role of p53 in cell death and human cancers

T Ozaki, A Nakagawara - Cancers, 2011 - mdpi.com
p53 is a nuclear transcription factor with a pro-apoptotic function. Since over 50% of human
cancers carry loss of function mutations in p53 gene, p53 has been considered to be one of …

Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer

C Thangavel, JL Dean, A Ertel… - Endocrine-related …, 2011 - erc.bioscientifica.com
The majority of estrogen receptor (ER)-positive breast cancers are treated with endocrine
therapy. While this is effective, acquired resistance to therapies targeted against ER is a …

[HTML][HTML] Sulforaphane-induced cell cycle arrest and senescence are accompanied by DNA hypomethylation and changes in microRNA profile in breast cancer cells

A Lewinska, J Adamczyk-Grochala, A Deregowska… - Theranostics, 2017 - ncbi.nlm.nih.gov
Cancer cells are characterized by genetic and epigenetic alterations and phytochemicals,
epigenetic modulators, are considered as promising candidates for epigenetic therapy of …

Recent advances in anti-cancer protein/peptide delivery

X Liu, F Wu, Y Ji, L Yin - Bioconjugate chemistry, 2018 - ACS Publications
Protein/peptide drugs possess unique advantages, such as high pharmacological potency,
molecular specificity, multifunctionality, and low toxicity, and thus hold great potential for use …

The immune system and inflammation in breast cancer

X Jiang, DJ Shapiro - Molecular and cellular endocrinology, 2014 - Elsevier
During different stages of tumor development the immune system can either identify and
destroy tumors, or promote their growth. Therapies targeting the immune system have …